Concentration-effect Relationship of Enoxaparin for Thromboembolic Prevention
Status:
Withdrawn
Trial end date:
2020-07-10
Target enrollment:
Participant gender:
Summary
Patients with COVID-19 have special demographic characteristics including thromboembolic risk
factors .
The pharmacokinetics of enoxaparin administered subcutaneously in the intensive care unit
patient are not described.
Finally, given the lack of knowledge on the pharmacokinetic/pharmacodynamic properties of
enoxaparin in intensive care unit patients infected with SARS-CoV-2, we propose to conduct a
prospective multicenter cohort study to collect the biological data necessary for its study.
Phase:
Phase 4
Details
Lead Sponsor:
Centre Hospitalier Universitaire de Saint Etienne
Collaborator:
CHU Saint-Etienne - Laboratoire de Pharmacologie - Toxicologie - Gaz du sang